PT  - JOURNAL ARTICLE
AU  - Lechien, Jerome R.
AU  - Cabaraux, Pierre
AU  - Chiesa-Estomba, Carlos M.
AU  - Khalife, Mohamad
AU  - Plzak, Jan
AU  - Hans, Stéphane
AU  - Martiny, Delphine
AU  - Calvo-Henriquez, Christian
AU  - Hopkins, Claire
AU  - Saussez, Sven
TI  - Objective olfactory testing in patients presenting with sudden onset olfactory dysfunction as the first manifestation of confirmed COVID-19 infection
AID  - 10.1101/2020.04.15.20066472
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.15.20066472
4099  - http://medrxiv.org/content/early/2020/04/18/2020.04.15.20066472.short
4100  - http://medrxiv.org/content/early/2020/04/18/2020.04.15.20066472.full
AB  - Background The aims of this study are to investigate the COVID-19 status of patients with initial sudden olfactory anosmia (ISOA) using nasopharyngeal swabs for RT-PCR analysis and to explore their olfactory dysfunctions with psychophysical olfactory evaluation.Methodology This prospective study included 78 ISOA patients who fulfilled a patient-reported outcome questionnaire and underwent a nasopharyngeal swabs. Among these, 46 patients performed psychophysical olfactory evaluation using sniffing tests. Based on the duration of the ISOA, two groups of patients were compared: patients with anosmia duration ≤12 days (group 1) and those with duration >12 days (group 2).Results Among group 1, 42 patients (87.5%) had a positive viral load regarding RT-PCR while 6 patients (12.5%) were negative. In group 2, 7 patients (23%) had a positive viral load and 23 patients (77%) were negative. Among the 46 patients having performed a psychophysical olfactory evaluation, we observed anosmia in 52% (N=24), hyposmia in 24% (N=11) and normosmia in 24% (N=11) of patients. The viral load significantly decreased throughout the 14-days following the onset of the olfactory disorder.Conclusions Our results support that a high proportion of ISOA patients are Covid+. Our study supports the need to add anosmia to the list of symptoms used in screening tools for possible COVID-19 infection.Competing Interest StatementThe authors have declared no competing interest.Funding Statementno fundAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available